SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is trending as investors react to a significant US commercialization deal with Tolmar, which provides both capital and infrastructure to de-risk the company's oncology platform. The community is actively discussing this validation, the stock's impressive pipeline of clinical trial catalysts, and growing institutional interest despite ongoing market volatility.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as retail and institutional investors anticipate significant momentum driven by global expansion efforts and pending near-term catalysts, including potential revenue growth and ongoing international regulatory progress. The community remains highly focused on the company's proprietary immunotherapy platform, expressing strong conviction that institutional accumulation will fuel a potential squeeze against high short interest.

Groupon, Inc. engages in the global scaled two-sided marketplace that connects consumers to merchants. It operates through the North America and International geographical segments. The company was founded by Andrew D. Mason, Eric Paul Lefkofsky, and Bradley A. Keywell in October 2008 and is headquartered in Chicago, IL.

Groupon Inc

Groupon is experiencing a surge in bullish sentiment driven by a combination of a significantly tight float and high short interest that has led investors to draw parallels to other major short squeeze events. The community is actively discussing the stock's potential for a parabolic move, pointing to aggressive share buybacks, internal restructuring efforts toward AI integration, and the mechanical pressure on short sellers as primary catalysts for continued upside.

Rackspace Technology, Inc. engages in the provision of end-to-end multi-cloud technology services. The firm designs, builds and operates its customers’ cloud environments across technology platforms. It operates through the following segments: Public Cloud and Private Cloud. The Public Cloud segment is a services-centric, capital-light model providing value-added cloud solutions through managed services, Elastic Engineering and professional services offerings for customer environments hosted on the AWS, Microsoft Azure and Google Cloud public cloud platforms. The Private Cloud segment is a technology-forward, capital-intensive model providing managed service offerings for customer environments hosted in data centers as well as in those owned by customers or by third parties such as colocation providers. The company was founded on July 21, 2016 and is headquartered in San Antonio, TX.

Rackspace Technology Inc

Rackspace Technology is currently trending following a definitive agreement with AMD to deploy AI compute infrastructure, a catalyst fueling optimism for its pivot into high-margin enterprise data center services. Community discourse is heavily split between bulls cheering the institutional validation and long-term potential, and bears highlighting the companys significant debt burden and potential for dilution.

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche is facing significant downward pressure and intense community scrutiny as investors express frustration over its performance relative to other major assets. Discussions are dominated by accusations of manipulation and project abandonment, with many traders debating the viability of long-term accumulation versus concerns about a potential value trap.

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Tempus AI Inc. - Ordinary Shares - Class A

Tempus AI Inc

Tempus AI is experiencing significant market interest driven by ongoing momentum in the healthcare AI sector and anticipation surrounding its upcoming investor day. Community discussions are heavily focused on the stock's high short interest and its potential as a long-term play in precision medicine, with many investors closely monitoring volume and institutional accumulation patterns.

FuboTV, Inc. is a consumer-first live TV streaming company with the mission of delivering premium sports, news and entertainment programming that offers greater choice, flexibility and value. The company was founded by David Gandler, Alberto Horihuela Suarez, and Sung Ho Choi on February 20, 2009 and is headquartered in New York, NY.

fuboTV Inc - Ordinary Shares - Class A

fuboTV Inc

Fubo remains a highly polarized ticker as investors weigh institutional ownership and potential short-squeeze dynamics against persistent concerns over management credibility and ongoing share price decline. The community is actively debating the company's long-term viability, often clashing over whether the stock represents a deep-value turnaround opportunity or a cautionary tale of persistent dilution and leadership distrust.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is currently trending as investors debate the potential of its ITK inhibitor, soquelitinib, with the community closely tracking upcoming Phase 2 data and potential M&A prospects. While some shareholders express enthusiasm over recent institutional buying and the stock's clinical pipeline, others remain cautious, highlighting the high-risk nature of its early-stage trials and the company's significant cash burn.

UNI is the governance token for Uniswap, an Automated Market Marker DEX on the Ethereum blockchain. The UNI token allows token holders to participate in the governance of the protocol. Key decisions such as usage of the treasury or future upgrades can be decided through a governance vote.

UniSwap

Uniswap is trending as community members closely monitor a governance proposal to activate the protocol's fee switch, which could redirect trading revenue to token holders and implement a significant token burn. Traders are actively debating the potential for this mechanism to improve long-term tokenomics while analyzing technical indicators and recent volume shifts to determine if a sustained price reversal is underway.

Cronos is an institutional-grade, high-performance, EVM-compatible Layer-1 blockchain built on the Cosmos SDK and integrated with the Inter-Blockchain Communication (IBC) protocol, designed as the backbone for open, compliant, and AI-accessible tokenized markets. It supports up to 60,000 transactions per second (TPS), 500ms block times, instant finality, and sub-$0.01 fees via Proof of Authority consensus.

Crypto.com Coin

Crypto.com Coin (CRO) is generating significant social media conversation as investors debate the impact of ongoing monthly token releases and potential regulatory shifts. The community remains deeply divided, with some users accumulating in anticipation of ecosystem expansions and ETF developments while others express frustration over dilution concerns and stagnant price action.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Seres Therapeutics (NASDAQ:MCRB) Releases Quarterly Earnings Results, Misses Estimates By $0.20 EPS

Seres Therapeutics (NASDAQ:MCRB - Get Free Report) announced its quarterly earnings data on Tuesday. The biotechnology company reported ($2.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.88) by ($0.20). The company had revenue of $0.36 million during the...

Seres Therapeutics (MCRB) Projected to Post Quarterly Earnings on Wednesday

Seres Therapeutics (NASDAQ:MCRB) will be releasing its Q1 2026 earnings before the market opens on Wednesday, May 6. (View Earnings Report at...

Seres Therapeutics (NASDAQ:MCRB) Shares Pass Below 200 Day Moving Average   - Here's What Happened

Seres Therapeutics (NASDAQ:MCRB) Share Price Crosses Below Two Hundred Day Moving Average - Time to Sell...

Seres Therapeutics (NASDAQ:MCRB) Stock Price Crosses Below Fifty Day Moving Average - Here's What Happened

Seres Therapeutics (NASDAQ:MCRB) Shares Cross Below 50 Day Moving Average - Here's Why...

Seres Therapeutics, Inc. (NASDAQ:MCRB) Short Interest Down 15.4% in February

Seres Therapeutics, Inc. (NASDAQ:MCRB - Get Free Report) was the recipient of a large decrease in short interest in the month of February. As of February 27th, there was short interest totaling...

Seres Therapeutics (NASDAQ:MCRB) Receives Buy Rating from Canaccord Genuity Group

Canaccord Genuity Group restated a "buy" rating and issued a $22.00 price target on shares of Seres Therapeutics in a research report on Friday...

Seres Therapeutics (NASDAQ:MCRB) Issues Earnings Results

Seres Therapeutics (NASDAQ:MCRB - Get Free Report) posted its quarterly earnings results on Thursday. The biotechnology company reported ($1.76) earnings per share for the quarter, beating analysts...

Seres Therapeutics (MCRB) Projected to Post Earnings on Thursday

Seres Therapeutics (NASDAQ:MCRB) will be releasing its Status update earnings before the market opens on Thursday, March 12. (View Earnings Report at...

Seres Therapeutics (NASDAQ:MCRB) Shares Cross Below 50-Day Moving Average - What's Next?

Seres Therapeutics (NASDAQ:MCRB) Stock Price Passes Below 50-Day Moving Average - Should You Sell...

Seres Therapeutics (NASDAQ:MCRB) Rating Lowered to Sell at Wall Street Zen

Wall Street Zen downgraded shares of Seres Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday...

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Seres Therapeutics Inc

MCRB Stock Declines As Seres Therapeutics Pauses SER-155 Phase 2 Study And Shrinks Headcount By 30%

Equity

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$2.18	--	--	N/A
Q1 '26	-$1.88	-$2.08	-10.64%	MISSED
Q4 '25	-$2.11	-$1.78	15.64%	BEAT
Q3 '25	$0.46	$0.94	105.84%	BEAT
Q2 '25	-$2.49	-$2.27	8.84%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

MCRBSeres Therapeutics Inc

Upcoming Earnings: Q2 '26

Historical Earnings

Latest MCRB News